scholarly journals Clinical implications of trials investigating drug‐drug interactions between cannabidiol and enzyme inducers or inhibitors or common antiseizure drugs

Epilepsia ◽  
2020 ◽  
Vol 61 (9) ◽  
pp. 1854-1868
Author(s):  
Philip N. Patsalos ◽  
Jerzy P. Szaflarski ◽  
Barry Gidal ◽  
Kevan VanLandingham ◽  
David Critchley ◽  
...  
Keyword(s):  
Drug Interactions ◽  
Clinical Implications ◽  
Enzyme Inducers

Reassessing Carbamazepine in the Treatment of Bipolar Disorder Clinical Implications of New Data

CNS Spectrums ◽  
2005 ◽  
Vol 10 (6) ◽  
pp. 1-2 ◽  
Author(s):  
Terence A. Ketter ◽  
David L. Ginsberg ◽  
Hagop S. Akiskal ◽  
Paul E. Keck ◽  
Richard H. Weisler ◽  
...  
Keyword(s):  
Bipolar Disorder ◽  
Weight Gain ◽  
Drug Interactions ◽  
Bipolar Depression ◽  
Panel Discussion ◽  
Current Data ◽  
Clinical Implications ◽  
Good Tolerability ◽  
Long Term Treatment

AbstractThis monograph summarizes the proceedings of a roundtable meeting convened to discuss the role of carbamazepine in the treatment of bipolar disorder, in light of new data and the recent indication of carbamazepine extended-release capsules (CBZ ERC) for use in the treatment of acute manic and mixed episodes. Two lectures were presented, followed by a panel discussion among all 6 participants. A summary of the two pivotal trials of CBZ ERC and their pooled data along with other relevant data is presented first. Next, historical trends of carbamazepine and the agent's use in acute mania, bipolar depression, and maintenance are reviewed, emphasizing clinical implications of efficacy, safety, tolerability, and drug interactions. Finally, the panel discussion provides recommendations for the use of carbamazepine in different phases of the illness, taking into account adverse effects and drug-drug interactions.Panel discussants agree that current data confirm the utility of CBZ ERC as an effective treatment for acute manic and mixed episodes in bipolar disorder. Carbamazepine may also prove to be an option for maintenance treatment. Tolerability of the drug is related to dose and titration, and overall safety limitations regarding carbamazepine usage are comparable to other medications. For some patients, the main challenges to use of carbamazepine may be common drug-drug interactions and increased side effects related to aggressive introduction during treatment of acute manic and mixed episodes. Thus, carbamazepine may be a lower priority option for patients who are taking multiple medications, such as elderly individuals with medical comorbidity, due to the potential for drug interactions. Important benefits of carbamazepine include the low propensity toward weight gain and evidence of good tolerability with long-term treatment. (At present there are no available data from long-term, placebo-controlled studies evaluating the effects of carbamazepine or CBZ ERC on weight.) Thus, carbamazepine may be a good option for patients who are concerned about weight gain or who are intolerant of or respond poorly to other medications. Further efforts are needed to update physicians on the use of carbamazepine relative to other medications in the treatment of bipolar disorder.

Drug-drug interactions involving lysosomes: mechanisms and potential clinical implications

2012 ◽  
Vol 8 (8) ◽  
pp. 943-958 ◽  
Author(s):  
Randall Logan ◽  
Ryan S Funk ◽  
Erick Axcell ◽  
Jeffrey P Krise
Keyword(s):  
Drug Interactions ◽  
Clinical Implications

Drug interactions with the taxanes: clinical implications

2001 ◽  
Vol 27 (4) ◽  
pp. 221-233 ◽  
Author(s):  
A.F. Baker ◽  
R.T. Dorr
Keyword(s):  
Drug Interactions ◽  
Clinical Implications

Phytocannabinoid drug-drug interactions and their clinical implications

2020 ◽  
Vol 215 ◽  
pp. 107621 ◽  
Author(s):  
Daniela Amaral Silva ◽  
David W. Pate ◽  
Robert D. Clark ◽  
Neal M. Davies ◽  
Ayman O.S. El-Kadi ◽  
...  
Keyword(s):  
Drug Interactions ◽  
Clinical Implications

Reassessing Carbamazepine in the Treatment of Bipolar Disorder Clinical Implications of New Data

CNS Spectrums ◽  
2005 ◽  
Vol 10 (S1) ◽  
pp. 1-2 ◽  
Keyword(s):  
Bipolar Disorder ◽  
Weight Gain ◽  
Drug Interactions ◽  
Bipolar Depression ◽  
Panel Discussion ◽  
Current Data ◽  
Clinical Implications ◽  
Good Tolerability ◽  
Long Term Treatment

ABSTRACTThis monograph summarizes the proceedings of a roundtable meeting convened to discuss the role of carbamazepine in the treatment of bipolar disorder, in light of new data and the recent indication of carbamazepine extended-release capsules (CBZ ERC) for use in the treatment of acute manic and mixed episodes. Two lectures were presented, followed by a panel discussion among all 6 participants. A summary of the two pivotal trials of CBZ ERC and their pooled data along with other relevant data is presented first. Next, historical trends of carbamazepine and the agent's use in acute mania, bipolar depression, and maintenance are reviewed, emphasizing clinical implications of efficacy, safety, tolerability, and drug interactions. Finally, the panel discussion provides recommendations for the use of carbamazepine in different phases of the illness, taking into account adverse effects and drug-drug interactions.Panel discussants agree that current data confirm the utility of CBZ ERC as an effective treatment for acute manic and mixed episodes in bipolar disorder. Carbamazepine may also prove to be an option for maintenance treatment. Tolerability of the drug is related to dose and titration, and overall safety limitations regarding carbamazepine usage are comparable to other medications. For some patients, the main challenges to use of carbamazepine may be common drug-drug interactions and increased side effects related to aggressive introduction during treatment of acute manic and mixed episodes. Thus, carbamazepine may be a lower priority option for patients who are taking multiple medications, such as elderly individuals with medical comorbidity, due to the potential for drug interactions. Important benefits of carbamazepine include the low propensity toward weight gain and evidence of good tolerability with long-term treatment. (At present there are no available data from long-term, placebo-controlled studies evaluating the effects of carbamazepine or CBZ ERC on weight. *) Thus, carbamazepine may be a good option for patients who are concerned about weight gain or who are intolerant of or respond poorly to other medications. Further efforts are needed to update physicians on the use of carbamazepine relative to other medications in the treatment of bipolar disorder.

scholarly journals The use of ginkgo biloba in the treatment of dementia

2001 ◽  
Vol 25 (9) ◽  
pp. 353-356 ◽  
Author(s):  
Ian Maidment
Keyword(s):  
Side Effects ◽  
Drug Interactions ◽  
Mechanism Of Action ◽  
Ginkgo Biloba ◽  
Cholinesterase Inhibitors ◽  
Clinical Implications ◽  
Medline Search

Aims and MethodTo assess and update the available data on use of ginkgo to treat dementia. A Medline search as conducted for the period January 1985 to October 2000. The search included other aspects of the usage of ginkgo, such as side-effects, mechanism of action and drug interactions.ResultsMost of the trials using ginkgo were to treat cerebral insufficiency. Only five trials could be identified that used ginkgo to treat dementia. There are no trials comparing ginkgo to cholinesterase inhibitors such as donepezil.Clinical ImplicationsGinkgo is generally well-tolerated and appears to ease the symptoms of dementia. Although it has been suggested that the effect is comparable to donepezil, confirmation from controlled studies is required.

Clopidogrel drug interactions: a review of the evidence and clinical implications

2020 ◽  
Vol 16 (11) ◽  
pp. 1079-1096 ◽  
Author(s):  
Chang Hoon Lee ◽  
Francesco Franchi ◽  
Dominick J. Angiolillo
Keyword(s):  
Drug Interactions ◽  
Clinical Implications
Sign in / Sign up

Export Citation Format

Share Document